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Volume 51, Number 11S Abstracts 91Sin the study.Main outcomes weremortality, complications,
reinterventions, and length of hospital stay.
Results: Fifty-eight patients (mean age 71 years (range
49-87), 53 (91%) males) with a total of 80 aortic and/or
iliac pseudo or true PAA were treated with an endovascular
stentgraft. Devices that were used were tube grafts (n 8),
bifurcated stentgrafts (n  32), aorto-uni-iliac stentgrafts
(n  7), and iliac extension grafts (n  11). Technical
success rate was 95%. Median hospital stay was 3 days
(range 1-122). The 30-day mortality rate was 3.4% (n 2).
Mean follow-up was 41 months (range 0-106). Procedure
related and cumulative mortality rate was 10% (n  6) and
19% (n  11), respectively. CTA revealed 9 endoleaks (3
type I and 6 type II) in 8 patients and endotension in 2
patients. Type I endoleaks were observed in 25% of patients
treated with endovascular tube grafts. The overall reinter-
vention rate was 19% (n 11) with an annual risk of 4.7%.
In non-tube graft patients the annual risk was 4.0%.
Conclusions: The present study shows that endovas-
cular repair with bifurcated or aorto-uni-iliac stentgrafts of
paraanastomotic aortic and iliac aneurysms after initial
prosthetic aortic surgery is a durable alternative to open
reconstruction.
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Objectives: AAA growth following endovascular aneu-
rysm repair (EVAR) in patients with type 2 endoleaks is
associated with adverse outcomes. We sought to evaluate
the success of embolization of type 2 endoleaks in prevent-
ing AAA sac growth.
Methods: We conducted a retrospective review of pa-
tients (pts) who underwent EVAR and were treated for a
type 2 endoleak. CT scans were evaluated for AAA size
from time of endoleak treatment. The embolization mate-
rial, graft, target, and co-morbidities were evaluated for
their association with change in sac size.
Results: Since 2000, 95 patients underwent 140 em-
bolizations to treat a type 2 endoleak. The median age was
77 (73, 83), 87% were men and 13% women. The mean
time from EVAR to embolization was 26.1/-22.2
months; the average increase in size of the AAA sac from
EVAR to treatment was 0.7x0.5 cm. The average number
of embolizations/patient post EVAR was 1.6  0.8. Thedistribution of vessels embolized at first and subsequent set-
tings were: ima- 37%/38%; lumbar- 38%/38%; proximal hy-
pogastric 11%/9%; AAA sac- 11%/14%; other 3%/2%. 13
patients underwent simultaneous embolization of two targets.
61% of patients were embolized with glue, 29% coils, 7% glue
& coils, and 3% gelfoam. 8 pts (8.4%) underwent graft ex-
plant. 19 (20%) of pts required two or more embolization
procedures. There was no difference between target vessel
treated or treatment modality in halting sac expansion (
5mm). No pt ruptured their AAA. One year cumulative
survival was 92% (87, 97.8), freedom from sac expansion (
5mm) 81.5% (72.6, 90.4), and freedom from second embo-
lization procedure 84.9 % (77.3, 92.5). Mutivariable analysis
identified continued tobaccouse to predict sac expansion (5
mm) 2.05 (0.88, 4.77; p 0.09).
Conclusions:Embolization of type 2 endoleaks prevents
AAA rupture and reduces AAA growth in the majority of pts
who have AAA growth and a type 2 endoleak following
EVAR.However, continued close surveillance is warranted in
a minority of patients who have continued sac growth.
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Objectives: To examine the fate of aneurysmal iliac
arteries managed during EVAR for AAA.
Methods: We analyzed data from the Cook Zenith
trial. Follow up was at 1, 6, 12 months, and annually for 5
years. Patients were evaluated according to the largest iliac
artery diameter: Group A (20mm) and Group B (
20mm). These groups were further subdivided based on
iliac artery growth  5mm during follow-up. The Fisher’s
exact test and chi square test were used.
Results: Of 736 patients treated, 671 had follow-up
(Group A 274). In Group A 220 (80%) were treated with
flared limbs in the common iliac artery. Group A did not
demonstrate increased iliac growth as compared to group
B. Furthermore, both groups had a similar percentage of
patients that experienced iliac artery expansion 32.1% and
31.5%. Extension to the external iliac artery did not affect
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June Supplement 201092S Abstractsgrowth (p  0.4). No difference was noted in the need for
secondary interventions between groups. However, group A
patients that did not experience growth were more likely to
develop a distal type I endoleak than groupBpatients whodid
not develop growth (p  0.03). There was no difference in
SAE between groups (p  0.51). However, patients that
developed iliac artery growth in either groupwere less likely to
have a SAE compared to patients who did not experience
growth (p  0.035). There was no difference in the mean
percent oversizing of the iliac limbs between groups A and B.
However, themean percent oversizing in groups A andB that
had iliac artery growth was significantly higher than in those
that demonstrated no growth (p 0.01).
Conclusions: Aneurysmal iliac arteries managed by
flared limbs or external iliac extensions at the time of EVAR
for AAA do not demonstrate future iliac growth, in-
creased rate of secondary interventions or serious adverse
events compared to patients with normal iliac arteries.
This suggests that aneurysmal iliac arteries can be safely
treated with appropriately-sized limbs landed in the
common or external iliac artery.
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Objectives: Male gender and family history are impor-
tant risk factor for abdominal aortic aneurysm (AAA). We
hypothesised that genes involved in sex hormones produc-
tion and action might be important in aortic dilatation. We
investigated the association of aortic diameter with single
nucleotide polymorphisms (SNPs) in genes determining
circulating sex hormones and their action.
Methods:Wegenotyped74 tagging SNPs across 4 genes
(steroid 5 reductase, subfamily A, polypeptide 1 (SRD5A1),
cytochrome P450, family 19, subfamily A, polypeptide 1
(CYP19A1), androgen receptor (AR) and estrogen receptor 2
(ESR2)) related to sex hormone production and action in
1711men, 640 ofwhomhad anAAA (mean diameter 36.1
6.7mm). Associations were assessed adjusting for other risk
factors for AAA, including age, smoking, coronary heart dis-
ease, hypertension, dyslipidemia and diabetes.
Results:One SNP inCYP19A1was strongly associated
with aortic diameter. Subjects who had the rare homozy-
gote genotype (TT) for CYP19A1 g.49412370CT (SNPID rs1961177), had increased aortic diameter (coefficient
4.872, standard error 1.394, p 0.0004, under a recessive
model adjusting for other risk factors). Four haplotypes in
CYP19A1 were demonstrated to be significantly associated
with aortic diameter, after adjusting for other risk factors
and multiple testing. In particular the relative common
haplotype CTT defined by the g.49386747CG (SNP ID
rs17523922), g.49394252CT (SNP ID rs3751591),
and g.49412370CT (SNP ID rs1961177) which was
present in 10% of men, p  0.0001.
Conclusions: Our findings support an association be-
tween one SNP in CYP19A1 and aortic diameter which
warrants validation in other cohorts.
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Objectives: To determine the incidence of disease pro-
gression and the need for subsequent revascularization
procedures in patients with Takayasu’s Arteritis (TA).
Methods: From 1980 - 2009, 40 patients (36 women,
mean age 35) with TA underwent an initial revasculariza-
tion procedure for end organ ischemia. The incidence of
subsequent revascularization in another vascular bed or
revision of the initial procedure was determined.
Results: Indications for the initial procedure were hyper-
tension (20), renal dysfunction (9), extremity ischemia (6),
and stroke/TIA (5). Initial revascularization included 36 by-
pass procedures and 4 endovascular interventions. Over a
mean follow-up of 6.4 years, 16 (40%) patients had either
progression of TA in another vascular bed or stenosis/occlu-
sion of the initial revascularization procedure. Five patients
with progression required 1 procedure whereas 11 required 2
or more surgical interventions. Procedures required included:
renal (11), carotid (5), extremity (5), iliac (2), subclavian (2),
abdominal aorta (2), thoracic aorta (1), and mesenteric (1).
Postoperative/30-day morbidity was 14% and there was one
operative death. One and 5-year actuarial survival were 94%
and 94%, respectively.
Conclusions: Progression of TA is a common occur-
rence in patients who require revascularization for end
organ ischemia. This finding emphasizes the need for
global lifelong vascular surveillance of all patients who
undergo surgical intervention for Takayasu’s steritis.
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